BIOPHARMA CREDIT DL -01
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.
BIOPHARMA CREDIT DL -01 (B3P) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOPHARMA CREDIT DL -01 (B3P) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOPHARMA CREDIT DL -01 - Net Assets Trend (None–None)
This chart illustrates how BIOPHARMA CREDIT DL -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOPHARMA CREDIT DL -01 (None–None)
The table below shows the annual net assets of BIOPHARMA CREDIT DL -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOPHARMA CREDIT DL -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOPHARMA CREDIT DL -01 Competitors by Market Cap
The table below lists competitors of BIOPHARMA CREDIT DL -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EmbedWay Tech(Shanghai)Corp
SHG:603496
|
$872.51 Million |
|
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
|
$872.92 Million |
|
Cancom SE
OTCGREY:CCCMF
|
$872.98 Million |
|
Kajaria Ceramics Limited
NSE:KAJARIACER
|
$873.14 Million |
|
Kepco Plant S&
KO:051600
|
$872.34 Million |
|
Open Up Group Inc.
PINK:BNXYF
|
$871.90 Million |
|
Daishin Sec
KO:003540
|
$871.17 Million |
|
OSOTSPA PCL-NVDR
BK:OSP-R
|
$870.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOPHARMA CREDIT DL -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOPHARMA CREDIT DL -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOPHARMA CREDIT DL -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOPHARMA CREDIT DL -01's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOPHARMA CREDIT DL -01 (B3P) | €- | N/A | N/A | $872.40 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |